EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

From Clinical Trials to Real-World Patients: Population Pharmacokinetics and Precision Dosing Simulations of Lorlatinib

Laura H Bukkems, Benoit Blanchet, Jennifer Arrondeau, Marie Wislez, Yan Wang, Henk-Jan Guchelaar, Egbert Smit, Dirk Jan A R Moes, Alicja Puszkiel

Clinical Pharmacokinetics · 2026-11 · 65 (11) · 1705-1714

DOI: 10.1007/s40262-026-01697-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 06.09.2026. Verfasst von Laura H Bukkems und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Models, Biological, Pyrazoles, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: The pharmacokinetics of lorlatinib have been characterized in a population pharmacokinetic (PK) model by the license holder, but external validation with real-world data is lacking. As higher trough concentrations are linked to increased toxicity, there may be a role for model-informed precision dosing (MIPD). METHODS: The published lorlatinib population PK model was externally validated using data from 150 patients with non-small cell lung cancer (NSCLC) treated in France and the Netherlands. Model performance was assessed using mean percentage error (MPE) and mean absolute percentage error (MAPE). Suboptimal validation results led to development of a refined population PK model, which was subsequently used to simulate lorlatinib exposure across different doses. A MIPD strategy targeting trough concentrations of 75-125 ng/mL was assessed. RESULTS: External validation revealed significant bias (MPE: -6.1%, 95% CI -11.1 to -0.5%), with the original population PK model systematically underestimating trough concentrations. The refined model included a lower clearance (13.7 versus 14.5 L/h). Simulations with the refined model predicted a median steady state trough level of 127.0 ng/mL (IQR: 96.1-162.0 ng/mL) versus 106.0 ng/mL with the original model for standard 100 mg once-daily (QD) regimen. MIPD increased the proportion of patients within target range from 35 to 62% after one cycle of dose adjustment. CONCLUSIONS: The published population PK model underestimates real-world trough concentrations, underscoring the importance of external validation of clinical trial-derived models. The refined model reflects lorlatinib pharmacokinetics in clinical practice better. Simulations suggest that lower lorlatinib doses may be feasible and MIPD may reduce toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalPyrazolesCarcinoma, Non-Small-Cell LungLung NeoplasmsLactams, MacrocyclicAntineoplastic AgentsHumansAminopyridinesLactamsFemaleMaleMiddle AgedAgedDose-Response Relationship, DrugComputer SimulationNetherlandsFrancePrecision Medicine

Substanzen

lorlatinibAminopyridinesLactamsPyrazolesLactams, MacrocyclicAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
  • Biologie du Médicament - Toxicologie, Cochin University Hospital, 27 rue du Faubourg Saint Jaques, 75014, Paris, France.
  • Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM - Université Paris Cité, Paris, France.
  • Department of Thoracic Oncology Unit, AP-HP, INSERM U1138, Centre de Recherches des Cordeliers, Paris Cancer Institute CARPEM, Université Paris Cité, Paris, France.
  • Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. D.J.A.R.Moes@lumc.nl.

Zitieren

APA

Bukkems, L. H., Blanchet, B., Arrondeau, J., Wislez, M., Wang, Y., Guchelaar, H. J., Smit, E., Moes, D. J. A. R., & Puszkiel, A. (2026). From Clinical Trials to Real-World Patients: Population Pharmacokinetics and Precision Dosing Simulations of Lorlatinib. Clinical Pharmacokinetics, 65(11), 1705-1714. https://doi.org/10.1007/s40262-026-01697-3

Vancouver

Bukkems LH, Blanchet B, Arrondeau J, Wislez M, Wang Y, Guchelaar HJ, et al. From Clinical Trials to Real-World Patients: Population Pharmacokinetics and Precision Dosing Simulations of Lorlatinib. Clinical Pharmacokinetics. 2026;65(11):1705-1714. doi:10.1007/s40262-026-01697-3

BibTeX
@article{Bukkems2026,
  author = {Bukkems, Laura H and Blanchet, Benoit and Arrondeau, Jennifer and Wislez, Marie and Wang, Yan and Guchelaar, Henk-Jan and Smit, Egbert and Moes, Dirk Jan A R and Puszkiel, Alicja},
  title = {From Clinical Trials to Real-World Patients: Population Pharmacokinetics and Precision Dosing Simulations of Lorlatinib},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  volume = {65},
  number = {11},
  pages = {1705--1714},
  doi = {10.1007/s40262-026-01697-3}
}
Kostenlos starten →